Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CBL-514 for reducing subcutaneous fat has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subcutaneous Fat Reduction

Drugs mentioned

• CBL-514

Snippet

Sponsor: Caliway Biopharmaceuticals Co., Ltd. | Conditions: Subcutaneous Fat | Phase 2 | Status: COMPLETED